DDInter1668 DDInter1376
Siltuximab is a chimeric (human-mouse) monoclonal immunoglobulin G1-kappa antibody produced in a Chinese hamster ovary (CHO) cell line by recombinant DNA technology. Siltuximab prevents the binding of IL-6 to soluble and membrane-bound IL-6 receptors by forming high affinity complexes with human interleukin-6 (IL-6). Its use is indicated for the treatment of adult patients with multicentric Castleman's disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative. MCD is a rare blood disorder caused by dysregulated IL-6 production, proliferation of lymphocytes, and subsequent enlargement of the lymph nodes. It is administered as a 1 hour intravenous infusion every 3 weeks.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Siltuximab {u} may cause a minor interaction that can limit clinical effects when taken with {v} Zinc gluconate
Siltuximab {u} may cause a minor interaction that can limit clinical effects when taken with {v} Vitamin E
Siltuximab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Diroximel fumarate
Siltuximab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Propafenone
Siltuximab {u} may lead to a major life threatening interaction when taken with {v} Etanercept
Siltuximab {u} may lead to a major life threatening interaction when taken with {v} Upadacitinib
Siltuximab may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate
Siltuximab may cause a minor interaction that can limit clinical effects when taken with Vitamin E
Siltuximab may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate
Siltuximab may cause a moderate interaction that could exacerbate diseases when taken with Propafenone
Siltuximab may lead to a major life threatening interaction when taken with Etanercept
Siltuximab may lead to a major life threatening interaction when taken with Upadacitinib